Across 246 leukemia Phase II and III trial geography records from 2024–2026, site activity was concentrated in a small group of recurring hematology centers. The top 10 EU sites accounted for 290 normalized site appearances, led by Vall d’Hebron with 45 appearances, CHU Nantes with 43, Rigshospitalet with 34, CHU Bordeaux with 33, and Charité Berlin with 32.
The top 10 institutions generated 290 normalized site appearances. Vall d’Hebron led with 45 of 290 top-10 appearances (15.5%), followed by CHU Nantes with 43 (14.8%), Rigshospitalet with 34 (11.7%), CHU Bordeaux with 33 (11.4%), and Charité Berlin with 32 (11.0%).
The leading leukemia site network is not distributed evenly across Europe. It is anchored by a small number of repeat hematology centers with broad adult and pediatric activity, making these institutions likely high-value feasibility targets for sponsors planning complex leukemia studies.
France contributed 100 of 290 top-10 site appearances (34.5%) through CHU Nantes, CHU Bordeaux and CHU Toulouse. Germany contributed 74 (25.5%) through Charité Berlin, Goethe University Frankfurt and University Hospital Cologne, while Spain contributed 68 (23.4%) through Vall d’Hebron and Hospital Universitario 12 de Octubre.
The top-site network is concentrated in three country clusters: France, Germany and Spain. Together they accounted for 242 of 290 top-10 site appearances (83.4%), indicating that leukemia trial feasibility in Europe is heavily shaped by repeat access to a small number of national hematology networks.
Phase II records accounted for 161 of 246 leukemia Phase II/III records (65.4%). Phase III accounted for 85 of 246 records (34.6%), showing that the observed EU site network is more strongly shaped by exploratory and mid-stage leukemia development than by confirmatory Phase III programs alone.
Because Phase II contributes nearly two-thirds of the dataset, the most active sites are likely not only large confirmatory-trial centers but also centers repeatedly used for biologically targeted, adaptive, pediatric, or early therapeutic leukemia programs.
The 2024 cohort contributed 164 of 246 records (66.7%), while 2025 contributed 61 (24.8%) and 2026 contributed 21 (8.5%). This makes 2024 the dominant source year for the current leukemia Phase II/III site map.
The site ranking mainly reflects 2024-authorized trial geography, with 2025 and 2026 adding newer but smaller layers of activity. For current feasibility planning, the repeated 2024–2026 presence of the same institutions is more informative than any single authorization year alone.
In this report, a site appearance means an institution appeared as a listed trial site within a leukemia Phase II or III geography record. Normalized site appearances combine equivalent institution variants, such as campus or spelling variants, into one institution-level count.
For leukemia Phase II/III trials, the strongest operational signal is not broad geographic spread but repeat use of established hematology centers. The evidence points to a feasibility strategy built around a small group of high-frequency institutions in Spain, France, Germany, Denmark and the Netherlands, then expanded with country-specific satellite sites for enrollment scale.